2/12
09:06 am
mrk
Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction [Seeking Alpha]
Low
Report
Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction [Seeking Alpha]
2/12
06:45 am
mrk
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
Low
Report
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
2/11
06:45 am
mrk
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS =1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
Low
Report
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS =1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
2/10
01:55 pm
mrk
Julien Nono-Womdim's Top Picks for Feb. 10, 2026 [BNN Bloomberg (Canada)]
Low
Report
Julien Nono-Womdim's Top Picks for Feb. 10, 2026 [BNN Bloomberg (Canada)]
2/9
01:45 pm
mrk
Merck: The Spike Doesn't Make It Overvalued [Seeking Alpha]
Low
Report
Merck: The Spike Doesn't Make It Overvalued [Seeking Alpha]
2/9
09:57 am
mrk
Merck: A Buy For 2026, But The Clock Is Still Ticking [Seeking Alpha]
Low
Report
Merck: A Buy For 2026, But The Clock Is Still Ticking [Seeking Alpha]
2/8
10:40 pm
mrk
From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade) [Seeking Alpha]
Medium
Report
From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade) [Seeking Alpha]
2/8
10:05 pm
mrk
Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum [Seeking Alpha]
Medium
Report
Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum [Seeking Alpha]
2/8
02:04 am
mrk
Merck & Co., Inc. (NYSE:MRK) was downgraded by analysts at
Wall Street Ze
Medium
Report
Merck & Co., Inc. (NYSE:MRK) was downgraded by analysts at
Wall Street Ze
2/7
11:56 am
mrk
Merck & Co., Inc. (MRK): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Merck & Co., Inc. (MRK): A Bull Case Theory [Yahoo! Finance]
2/6
10:34 am
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Guggenheim from $122.00 to $140.00. They now have a "buy" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Guggenheim from $122.00 to $140.00. They now have a "buy" rating on the stock.
2/5
08:23 pm
mrk
????????:2032????66?5000??????????????(CAGR)8.1%??? [CNET News]
Low
Report
????????:2032????66?5000??????????????(CAGR)8.1%??? [CNET News]
2/5
01:28 pm
mrk
Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut [Yahoo! Finance Canada]
Low
Report
Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut [Yahoo! Finance Canada]
2/5
07:46 am
mrk
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants [Globe and Mail, The (Toronto, Canada)]
Low
Report
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants [Globe and Mail, The (Toronto, Canada)]
2/4
09:01 pm
mrk
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO [Yahoo! Finance]
Low
Report
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO [Yahoo! Finance]
2/4
03:47 pm
mrk
Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks” [Yahoo! Finance]
Low
Report
Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks” [Yahoo! Finance]
2/4
02:52 pm
mrk
Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda [FOX Business Network]
Low
Report
Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda [FOX Business Network]
2/4
01:32 pm
mrk
Where is Merck & Co. (MRK) Headed According to Wall Street? [Yahoo! Finance]
Low
Report
Where is Merck & Co. (MRK) Headed According to Wall Street? [Yahoo! Finance]
2/4
01:16 pm
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Citigroup Inc. from $115.00 to $120.00. They now have a "neutral" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Citigroup Inc. from $115.00 to $120.00. They now have a "neutral" rating on the stock.
2/4
11:36 am
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Cantor Fitzgerald from $116.00 to $120.00. They now have a "neutral" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Cantor Fitzgerald from $116.00 to $120.00. They now have a "neutral" rating on the stock.
2/4
10:42 am
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Wells Fargo & Company from $125.00 to $135.00. They now have an "overweight" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Wells Fargo & Company from $125.00 to $135.00. They now have an "overweight" rating on the stock.
2/4
01:21 am
mrk
Merck & Co., Inc. Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Merck & Co., Inc. Q4 Earnings Call Highlights [Yahoo! Finance]
2/3
11:27 pm
mrk
Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year [Yahoo! Finance]
Low
Report
Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year [Yahoo! Finance]
2/3
02:36 pm
mrk
Are Wall Street Analysts Bullish on Moderna Stock? [Yahoo! Finance]
Low
Report
Are Wall Street Analysts Bullish on Moderna Stock? [Yahoo! Finance]
2/3
01:35 pm
mrk
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript [Seeking Alpha]